About MiroBio
MiroBio is a company based in Oxford (United Kingdom) founded in 2019 by Simon Davis and Richard Cornall was acquired by Gilead in August 2022.. MiroBio has raised $131.81 million across 3 funding rounds from investors including Gilead, Orbimed and Medicxi. The company has 29 employees as of December 31, 2021. MiroBio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
- Headquarter Oxford, United Kingdom
- Employees 29 as on 31 Dec, 2021
- Founders Simon Davis, Richard Cornall
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mirobio Ltd
- Date of Incorporation 08 Oct, 2018
- Jurisdiction GARSINGTON, OXFORD, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
$-37.53 M (USD)-181as on Jul 31, 2022
-
EBITDA
$-42.79 M (USD)-169as on Jul 31, 2022
-
Total Equity Funding
$131.81 M (USD)
in 3 rounds
-
Latest Funding Round
$97 M (USD), Series B
Jun 21, 2022
-
Investors
Gilead
& 7 more
-
Employee Count
29
as on Dec 31, 2021
-
Acquired by
Gilead
(Aug 04, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
294 people
Software Development Team
183 people
Senior Team
62 people
Legal and Compliance
41 people
Data Analysis and Operations Team
38 people
Human Resources and Administration
38 people
Operations Team
38 people
Finance and Accounting
36 people
Unlock access to complete
Funding Insights of MiroBio
MiroBio has successfully raised a total of $131.81M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $97 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $97.0M
-
First Round
First Round
(15 Apr 2019)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series B - MiroBio | Valuation | Medicxi | |
| Apr, 2022 | Amount | Series A - MiroBio | Valuation |
investors |
|
| Apr, 2019 | Amount | Series A - MiroBio | Valuation | Oxford Science Enterprises , Samsara BioCapital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MiroBio
MiroBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Orbimed and Medicxi. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location | |
|
Early and mid-stage life science focused VC firm investing in the US and Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MiroBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MiroBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mirobio Comparisons
Competitors of MiroBio
MiroBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mirobio
Frequently Asked Questions about MiroBio
When was MiroBio founded?
MiroBio was founded in 2019.
Where is MiroBio located?
MiroBio is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Who is the current CEO of MiroBio?
Eliot Charles is the current CEO of MiroBio.
Is MiroBio a funded company?
MiroBio is a funded company, having raised a total of $131.81M across 3 funding rounds to date. The company's 1st funding round was a Series A of $34M, raised on Apr 15, 2019.
How many employees does MiroBio have?
As of Dec 31, 2021, the latest employee count at MiroBio is 29.
What does MiroBio do?
Developer of therapeutics for auto-immune diseases. The company has developed a platform to develop antibiotics that activate natural mechanisms to control over-active immune responses that cause these diseases.
Who are the top competitors of MiroBio?
Who are MiroBio's investors?
MiroBio has 8 investors. Key investors include Gilead, Orbimed, Medicxi, SR One, and Advent Life Sciences.
What is MiroBio's valuation?
The valuation of MiroBio is $25.5M as of Apr 2022.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.